1.240USD0.00%Mkt Cap: —P/E: —1d ago
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), c…
Industry Peers
Biotechnology$130.23BUSDP/E 32.1
$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
Key Statistics
Company
Market Cap—
Enterprise Value87.13M $
Revenue (TTM)0 $
Gross Profit-54.21M $
Net Income (TTM)-67.43M $
Revenue/Share0.0000 USD
Last Price1.240 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees112
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINUS45773H2013
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-1.12
EV/Revenue—
P/S—
P/B27.98
EPS (TTM)-1.54
EPS (Forward)—
52W Range
1.07061% of range1.350
52W High1.350 USD
52W Low1.070 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-409.87%
ROA-84.23%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-80.58M $
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-28.67M $
Net Debt/EBITDA0.37
Balance Sheet
Debt/Equity183.07
Current Ratio1.00
Quick Ratio0.92
Book Value/Sh0.0420 USD
Cash/Share0.3550 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split0.083333:1
Split DateJan 25, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float95.70M
Insiders0.33%
Institutions46.01%
Technical
SMA 505.531 (-77.6%)
SMA 2001.722 (-28.0%)
Beta—
S&P 52W Chg20.80%
Avg Vol (30d)62.02K
Avg Vol (10d)15.80K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—